| Aug 7 |
Immutep to Participate in Upcoming Investor Conferences
|
| Jul 31 |
Immutep Quarterly Activities Report Q4 FY24
|
| Jul 22 |
Immutep gains positive feedback from FDA on phase 3 NSCLC candidate program
|
| Jul 22 |
Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer
|
| Jul 17 |
Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases
|
| Jul 15 |
Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs
|
| Jul 15 |
Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals
|
| Jul 12 |
Biggest stock movers today: WFC, TSLA, ERIC, and more
|
| Jul 12 |
Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars
|
| Jul 12 |
Immutep gains after positive results from cancer trial
|
